Woodline Partners LP C4 Therapeutics, Inc. Transaction History

Woodline Partners LP

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 15, 2021	SELL	$35.91 - $50.5 $931,002 - $1.31 Million	-25,926 Closed	0 $0
Q2 2021 Aug 16, 2021	SELL	$30.39 - $42.18 $884,288 - $1.23 Million	-29,098 Reduced 52.88%	25,926 $981,000
Q1 2021 May 17, 2021	SELL	$31.96 - $46.5 $3.56 Million - $5.18 Million	-111,299 Reduced 66.92%	55,024 $2.04 Million
Q4 2020 Feb 16, 2021	BUY	$22.8 - $37.05 $3.79 Million - $6.16 Million	166,323 New	166,323 $5.51 Million

130

63.5M

670K

54.8K

Ticker CCCC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 48,913,800
Market Cap $199M
Description
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting ...

Get notified when there are updates to the investment portfolio of Woodline Partners LP, based on Form 13F filings with the SEC.

Stay updated on Woodline Partners LP with notifications on news.